Sign In
Buy AKBA
$0.84
-0.0659 (-7.24%)
At Close: Aug 10, 2026
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
09:10am, Thursday, 13'th Mar 2025
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating pla
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights
08:00am, Thursday, 06'th Mar 2025
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended Decemb
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 04'th Mar 2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline
05:43am, Monday, 10'th Feb 2025
Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's sig
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 04'th Feb 2025
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Announces Multiple Positive Business Updates
08:00am, Monday, 13'th Jan 2025
New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping i
New Strong Sell Stocks for January 3rd
06:05am, Friday, 03'rd Jan 2025
AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 02'nd Jan 2025
CAMBRIDGE, Mass. , Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 18'th Dec 2024
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
New Strong Sell Stocks for December 5th
06:51am, Thursday, 05'th Dec 2024
AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 03'rd Dec 2024
CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, gran
Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc
New Strong Sell Stocks for November 27th
05:46am, Wednesday, 27'th Nov 2024
AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024.
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
08:00am, Monday, 25'th Nov 2024
CAMBRIDGE, Mass. , Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
